---
title: "BOYA BIOLOGY released its performance for the first half of the year, with a net profit attributable to the parent company of 225 million yuan, a decrease of 28.68%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254124243.md"
description: "According to the Zhitong Finance APP, BOYA BIOLOGY released its semi-annual report for 2025, showing an operating income of 1.008 billion yuan, a year-on-year increase of 12.51%. The net profit attributable to shareholders of the listed company was 225 million yuan, a year-on-year decrease of 28.68%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 166 million yuan, a year-on-year decrease of 36.05%. The basic earnings per share were 0.45 yuan"
datetime: "2025-08-22T08:41:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254124243.md)
  - [en](https://longbridge.com/en/news/254124243.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254124243.md)
generator: "portal-rs"
---

# BOYA BIOLOGY released its performance for the first half of the year, with a net profit attributable to the parent company of 225 million yuan, a decrease of 28.68%

According to the Zhitong Finance APP, BOYA BIOLOGY (300294.SZ) released its semi-annual report for 2025, reporting an operating income of 1.008 billion yuan, a year-on-year increase of 12.51%. The net profit attributable to shareholders of the listed company was 225 million yuan, a year-on-year decrease of 28.68%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 166 million yuan, a year-on-year decrease of 36.05%. The basic earnings per share were 0.45 yuan

### Related Stocks

- [300294.CN](https://longbridge.com/en/quote/300294.CN.md)

## Related News & Research

- [Lenzing shareholders approve EUR 300 million capital increase at extraordinary meeting](https://longbridge.com/en/news/296902548.md)
- [04:21 ETNew Real-World Data Show penKid Adding Decision Support for Kidney Replacement Therapy in Critical Care](https://longbridge.com/en/news/297147475.md)
- [LB Group : Revenue up 8.15% but net profit down 39.08% amid cost pressures and major share buyback](https://longbridge.com/en/news/297034690.md)
- [SANASA board reviews Interactive Water Museum presentation at Aug. 27 meeting](https://longbridge.com/en/news/297217847.md)
- [09:30 ETInnovation Through Collaboration Puts Precision BioLogic on the Map in Hemostasis Diagnostics and Research](https://longbridge.com/en/news/297194649.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**